Department of Medicine, University of Alberta, Edmonton, Canada.
Department of Mathematical and Statistical Sciences, University of Alberta, Edmonton, Canada.
Transplantation. 2018 Sep;102(9):1553-1562. doi: 10.1097/TP.0000000000002146.
Posttransplant lymphoproliferative disorders (PTLD) are a complication of solid organ transplantation (SOT) associated with Epstein-Barr virus (EBV).
We analyzed the incidence of and risk factors for PTLD among adult SOT recipients at our center over 30 years (1984-2013). We also compared PTLD incidence before and after a prevention strategy of EBV viral load monitoring in EBV serology mismatched patients was adapted in 2001 (ie, transplant era 1 [1983-2001] vs era 2 [2002-2013]).
Among 4171 SOT patients, 109 developed PTLD. Cumulative incidence at 1, 10, and 20 years posttransplant was 0.95, 2.3, and 3.5 per 100 person-years, respectively. Beyond the first year peak of almost exclusively EBV-positive PTLD, a lower incidence of PTLD, predominantly EBV negative, persisted for 20 years. Thoracic transplant (hazard ratio [HR], 2.1; P = 0.007) and negative EBV serology (HR, 7.7; P < 0.001) were independent risk factors for PTLD on multivariate Cox regression analysis. EBV seronegativity significantly increased risk of early (HR, 18.5) and EBV-positive PTLD (HR, 14.2), as well as late (HR, 4.9) and EBV-negative PTLD (HR, 3.6) on univariate analyses. Risk of early PTLD was significantly reduced in the recent transplant era (0.8% era 2 vs 1.9% era 1 at 5 years, P = 0.002); this reduction was seen in recent era EBV seropositive (P = 0.035 at 5 years) but not seronegative recipients (P = 0.90 year 5), suggesting lack of impact of viral load monitoring.
Adult SOT recipients face a prolonged risk of late PTLD, whereas risk of early PTLD may have declined in recent years.
移植后淋巴组织增生性疾病(PTLD)是实体器官移植(SOT)的并发症,与 EBV 有关。
我们分析了本中心 30 多年(1984-2013 年)来 SOT 受者中 PTLD 的发生率和危险因素。我们还比较了 2001 年采用 EBV 病毒载量监测预防策略前后(即移植时代 1[1983-2001]与时代 2[2002-2013])PTLD 的发生率。
在 4171 例 SOT 患者中,109 例发生了 PTLD。移植后 1、10 和 20 年的累积发生率分别为 0.95、2.3 和 3.5/100 人年。在 EBV 阳性 PTLD 几乎全部为第一年高峰后,PTLD 的发生率持续 20 年下降,主要为 EBV 阴性。胸移植(HR 2.1;P = 0.007)和 EBV 阴性血清学(HR 7.7;P <0.001)是多因素 Cox 回归分析中 PTLD 的独立危险因素。EBV 血清阴性显著增加了早期(HR 18.5)和 EBV 阳性 PTLD(HR 14.2)、晚期(HR 4.9)和 EBV 阴性 PTLD(HR 3.6)的风险。在最近的移植时代,早期 PTLD 的风险显著降低(0.8%时代 2 与 1.9%时代 1 在 5 年时,P = 0.002);这一降低在最近时代 EBV 血清阳性(P = 0.035 在 5 年)而不是血清阴性(P = 0.90 在 5 年)的患者中可见,表明病毒载量监测没有影响。
成人 SOT 受者面临长期的晚期 PTLD 风险,而近年来早期 PTLD 的风险可能已经降低。